✦ LIBER ✦

Dose-limiting dermatological toxicity secondary to imatinib mesylate (STI571) in chronic myeloid leukaemia

✍ Scribed by Milojkovic, D; Short, K; Salisbury, J R; Creamer, D; du Vivier, A W P; Mufti, G J

Book ID: 110055526
Publisher: Nature Publishing Group
Year: 2003
Tongue: English
Weight: 127 KB
Volume: 17
Category: Article
ISSN: 0887-6924
DOI: 10.1038/sj.leu.2402991

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Resistance to imatinib mesylate in chron

Resistance to imatinib mesylate in chronic myeloid leukaemia

✍ Junia V. Melo; Charles Chuah 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 416 KB

Chronic myeloid leukemia in a patient wi

Chronic myeloid leukemia in a patient with chronic idiopathic thrombocytopenic purpura: Rapid response to imatinib mesylate (STI571)

✍ Imashuku, Shinsaku ;Morimoto, Akira ;Kuriyama, Kikuko ;Kano, Gen ;Hibi, Shigeyos 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 46 KB

The novel pyrrolo-1,5-benzoxazepine, PBO

The novel pyrrolo-1,5-benzoxazepine, PBOX-21, potentiates the apoptotic efficacy of STI571 (imatinib mesylate) in human chronic myeloid leukaemia cells

✍ Sandra A. Bright; Lisa M. Greene; Tom F. Greene; Giuseppe Campiani; Stefania But 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 905 KB

Acute Renal Failure Secondary to Imatini

Acute Renal Failure Secondary to Imatinib Mesylate Treatment in Chronic Myeloid Leukemia

✍ Pou, Monica; Saval, Nuria; Vera, Manel; Saurina, Anna; Solé, Manel; Cervantes, F 📂 Article 📅 2003 🏛 Informa plc 🌐 English ⚖ 98 KB

Imatinib mesylate (STI571) abrogates the

Imatinib mesylate (STI571) abrogates the resistance to doxorubicin in human K562 chronic myeloid leukemia cells by inhibition of BCR/ABL kinase-mediated DNA repair

✍ Ireneusz Majsterek; Tomasz Sliwinski; Tomasz Poplawski; Dariusz Pytel; Michal Ko 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 233 KB

Cytogenetic and molecular responses in c

Cytogenetic and molecular responses in chronic phase chronic myeloid leukaemia patients receiving low dose of imatinib for intolerance to standard dose

✍ Massimo Breccia; Laura Cannella; Caterina Stefanizzi; Roberto Latagliata; Mauro 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 76 KB

## Abstract Imatinib mesylate is the gold standard treatment of chronic myeloid leukaemia (CML) and 400 mg/day is considered the standard dose. Although it is generally well tolerated, some patients require temporary drug discontinuation and permanent dose reduction because of haematological or non